Business Description
Brainstorm Cell Therapeutics Inc
NAICS : 325412
SIC : 2836
ISIN : US10501E2019
Total Employee Number:
19Description
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.01 | |||||
Equity-to-Asset | -14.58 | |||||
Debt-to-Equity | -0.14 | |||||
Debt-to-EBITDA | -0.17 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 52.9 | |||||
3-Year EPS without NRI Growth Rate | 51.5 | |||||
3-Year FCF Growth Rate | 54.4 | |||||
3-Year Book Growth Rate | 9.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 28.51 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.02 | |||||
Quick Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -65.2 | |||||
Shareholder Yield % | -29.51 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -514.85 | |||||
ROIC % | -233.97 | |||||
3-Year ROIIC % | -327.15 | |||||
ROC (Joel Greenblatt) % | -1359.89 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -1.7 | |||||
EV-to-EBITDA | -1.73 | |||||
EV-to-Forward-Revenue | 4.39 | |||||
EV-to-FCF | -2.37 | |||||
Earnings Yield (Greenblatt) % | -58.92 | |||||
FCF Yield % | -48.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Brainstorm Cell Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.792 | ||
| Beta | 2.3965 | ||
| 3-Year Sharpe Ratio | -0.17 | ||
| 3-Year Sortino Ratio | -0.23 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 2.979 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 2.979 - 2.979 | ||
| Shares Outstanding (Mil) | 11.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Brainstorm Cell Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Brainstorm Cell Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 128 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 08:30 | In 38 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 37 days | ||
| General meeting for 2026 | 2026-07-09 10:00 | In 2 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 2.98 (+0.00%) | ||
| Annual report for 2025 | 2026-03-31 | 2.98 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 2.98 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 2.98 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-14 08:30 | 2.98 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 2.98 (+0.00%) |
Show
Entries
Brainstorm Cell Therapeutics Inc Frequently Asked Questions
What is Brainstorm Cell Therapeutics Inc(STU:GHD)'s stock price today?
The current price of STU:GHD is €2.98. The 52 week high of STU:GHD is €2.98 and 52 week low is €2.98.
When is next earnings date of Brainstorm Cell Therapeutics Inc(STU:GHD)?
The next earnings date of Brainstorm Cell Therapeutics Inc(STU:GHD) is 2026-08-14 Est..
Does Brainstorm Cell Therapeutics Inc(STU:GHD) pay dividends? If so, how much?
Brainstorm Cell Therapeutics Inc(STU:GHD) does not pay dividend.
Press Release
Articles on Brainstorm Cell Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers